Related Experiment Video
Updated: Jun 13, 2026
Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
Published on: August 24, 2019
Defining disease stability in COPD: Evidence from Phase 3 clinical trials
Dave Singh1,2, Rianne Stacey3, David M G Halpin4
1Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, University of Manchester, Manchester University NHS Foundation Trust, Manchester, UK.
Rationale:
Disease stability in COPD is a low disease activity state proposed as a treatment target.
Objectives:
Characterize COPD stability as a composite endpoint.
Methods:
Post hoc analyses were carried out on IMPACT and FULFIL (fluticasone furoate/umeclidinium/vilanterol [FF/UMEC/VI] vs dual therapies) and MATINEE/METREX/METREO (mepolizumab added onto triple therapy). Stability was defined as "no moderate/severe exacerbations and no worsening from baseline in CAT and FEV1". We assessed whether achieving stability at Week 28 was prognostic of subsequent outcomes (time to first on-treatment moderate/severe exacerbation and time to all-cause mortality [ACM]) after Week 28 (IMPACT). Bayesian joint modeling evaluated the probability of achieving stability (IMPACT).
Measurements And Main Results:
Stability was achieved with FF/UMEC/VI by 22% of patients in IMPACT (Week 52) and by 46% of patients in FULFIL (Week 24); stability was achieved with mepolizumab +triple therapy by 18% of patients in MATINEE/METREX/METREO (Week 52). Patients were more likely to achieve stability with triple versus dual therapy and with mepolizumab versus placebo. Many individuals achieving stability had clinically meaningful improvements in CAT and FEV1. Patients achieving stability at Week 28 (vs patients who were not stable) had a 45.7% reduction in the risk of moderate/severe exacerbations and a 51.7% reduction in the risk of ACM after Week 28. Bayesian joint modeling demonstrated a mean (SD) posterior probability of stability: 25.60% (0.66) at Week 52 (FF/UMEC/VI).
Conclusions:
Our data provide further evidence for disease stability as an achievable COPD treatment target that predicts long-term clinical benefits in exacerbations and mortality.
Related Concept Videos
01:20COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:19Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
01:24Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...